Navigation Links
Most Leukemia Patients Recover From 'Chemo Brain' After Transplant: Study
Date:5/6/2011

FRIDAY, May 6 (HealthDay News) -- A decline in memory and fine-motor skills is common among patients who undergo a bone marrow or stem cell transplant to treat leukemia or lymphoma, but most patients return to normal within five years, according to a new study.

Previous research has shown that the chemotherapy drugs these patients take before transplantation and medicines they take to prevent rejection of the transplanted cells can affect memory and motor skills. This study looked at how long it takes them to recover from those problems, often referred to as "chemo brain."

The study included 92 patients with chronic myeloid leukemia, acute leukemia, lymphoma or myelodysplastic syndrome, in which the bone marrow does not function normally. The patients had received an allogeneic (cells donated by another person) bone marrow or stem cell transplant.

After treatment, the patients' memory and motor skills were assessed. Most patients showed substantial improvement in neurocognitive function between one and five years after their transplant.

But deficits, described as mostly mild, persisted for five years in nearly 42 percent of the patients, a finding that surprised the researchers at the Fred Hutchinson Cancer Research Center in Seattle.

"We really thought the rates would be lower," study leader Karen Syrjala, director of Biobehavioral Sciences, said in a Hutchinson news release. "We were thrilled to see that people recovered substantially, but we also were surprised that so many people did continue to have measurable deficits in some areas even after five years."

Further research is needed to identify the reasons for these persistent deficits, she added.

The study was published May 2 online in the Journal of Clinical Oncology.

More information

The U.S. National Heart, Lung, and Blood Institute has more about bone marrow and stem cell transplant.

-- Robert Preidt

SOURCE: Fred Hutchinson Cancer Research Center, news release, May 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Agent selectively targets malignant B cells in chronic leukemia, study shows
2. Possible new approach to treating deadly leukemia in babies
3. New drug shows potential for treatment-resistant leukemia
4. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
5. Tracking down the origin of leukemia relapse
6. New approach to leukemia chemotherapy -- is a cure in sight?
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
9. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
10. Less Is More With Acute Myeloid Leukemia Drug
11. When leukemia returns, gene that mediates response to key drug often mutated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo Valley ... who successfully complete the seven-week long Patient Care Academy are eligible to take the ... salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one is ...
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Ten outstanding ... Union's Stars in the Classroom and will win a visit by a Houston Texans ... K-12 who are at least five years old can visit texanschecking.com/stars to nominate their ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... N.J. , Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief ... increase antibody titer and present new data on Cell-Ess® Universal ... in Boston, MA August 21-25.  The Bioprocessing Summit ... today,s bioprocess challenges. ... and Optimizer ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
Breaking Medicine Technology: